HOW DO YOU ACCURATELY MEASURE YOUR DRUG’S IMPACT ON PATIENTS’ PULMONARY FUNCTION?
Non-respiratory indications, like Amyotrophic Lateral Sclerosis (ALS), Systemic Sclerosis, Crohn’s Disease and Pompe’s Disease impair the respiratory muscles and eventually progress to respiratory dysfunction or failure. Alpha-1 antitrypsin deficiency (A1AD) is a genetic disease that eventually lead to lung disease, like COPD. Pulmonary function tests (PFT), including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) are used as measurement of disease progression.
ERT’S Integrated Respiratory Safety and Disease Progression Solution
ERT enables precise lung function testing to measure both the drug effect and progress of the disease using purpose-built devices and software customized to your protocol workflow for nearly 100% acceptable data in real time.
Non-Respiratory Diseases That Affect the Lungs
Indications that impair respiratory muscles and include pulmonary function testing to monitor disease progression include:
- Amyotrophic Lateral Sclerosis
- Systemic Sclerosis
- Crohn’s Disease
- Pompe’s Disease
- Duchenne Muscular Dystrophy
- Rheumatoid Arthritis
- Multiple Sclerosis
- Pulmonary Hypertension
- Graft Versus Host Disease
- Guillain- Barre Syndrome
- Myathemia Gravis
Experts in Respiratory Solutions
LEARN MORE ABOUT HOW ERT CAN SUPPORT YOUR CLINICAL TRIAL WITH AN INTEGRATED SOLUTION
Hover over a test below to see the device.
Integrated Hub for Spirometry that measures lung function and cardiac safety endpoints, and integrates with Imaging endpoint collection and eCOA. Collects FVC, FEV1, PEF, ECG, FeNO, and airway resistance measurements.
Smart, portable, and affordable system for the measurement, recording, and assessment of accurate lung function parameters. Collects FVC, FEV1, and PEF.
Ndd EasyOne Pro® LAB
(integrates with MasterScope) – Portable, easy to use DLCO used in detecting, characterizing, and quantifying the severity of lung disease. Collects DLCO
Easy-to-use home spirometer and electronic diary (eDiary) measures and saves all relevant expiratory flow-volume parameters and records symptoms, events and medication. Collects FEV1 and PEF.
A home spirometry sensor in conjunction with the iSpiro App collects full spirometry at home, enabling remote collection of pulmonary endpoints. Collects FVC, FEV1, and PEF.
Collects respiratory patient questionnaires for real-time insights into patient safety and study performance.
Captures, reads, and stores ECGs centrally to avoid the risk of false or inaccurate data.
Measures and analyzes imaging endpoints like chest computed tomography (CT) to provide in-demand evidence of drug safety and efficacy.
Talk to a Specialist
Our team of experts is available to address questions you may have about our integrated respiratory solutions. Submit your contact information and we’ll be in touch shortly.